VIVORYON THERAPEUTICS AG Inactive Instrument
Vivoryon Therapeutics AG Stock Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
| Sales 2023 | -3.62K -3.87K | Sales 2024 * | - | Capitalization | 23.33M 24.97M |
|---|---|---|---|---|---|
| Net income 2023 | -28M -29.97M | Net income 2024 * | -18M -19.26M | EV / Sales 2023 | -53,497 x |
| Net cash position 2023 | 18.52M 19.82M | Net cash position 2024 * | 19.55M 20.92M | EV / Sales 2024 * | - |
| P/E ratio 2023 |
-7.27
x | P/E ratio 2024 * |
-1
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics AG
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
01:00am
- Q4 2023 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +3.75% | 43.43B | |
| +47.81% | 41.69B | |
| +9.29% | 41.31B | |
| -10.92% | 27.14B | |
| +8.92% | 25.28B | |
| -24.99% | 18.47B | |
| +29.96% | 12.59B | |
| +0.77% | 12.33B | |
| +8.53% | 11.03B |
